Group 1 - Soleno Therapeutics, Inc. is participating in several investor conferences in February and March 2026, including the Guggenheim Emerging Outlook: Biotech Summit, Oppenheimer 36th Annual Healthcare Life Sciences Conference, and TD Cowen 46th Annual Health Care Conference [1] - The company’s first commercial product, VYKAT™ XR (diazoxide choline) extended-release tablets, was approved by the FDA on March 26, 2025, for the treatment of hyperphagia in individuals with Prader-Willi syndrome aged 4 years and older [2]

Core Viewpoint - Soleno Therapeutics, Inc. (NASDAQ:SLNO) is identified as a stock with significant upside potential, with multiple analysts maintaining bullish outlooks despite some mixed signals regarding its performance [1][2]. Group 1: Analyst Ratings and Price Targets - H.C. Wainwright raised the target price for SLNO from $110 to $120, indicating strong confidence in the stock's future performance [1]. - Wells Fargo analyst Derek Archila maintained a price target of $106, reflecting a positive sentiment towards the stock [1]. - Cantor Fitzgerald's Kristen Kluska reiterated a Buy rating with a price target of $123, further supporting the bullish outlook [1]. - Wolfe Research cut its price target from $75 to $60 but still maintains a Buy rating, suggesting a potential upside of 41.7% from current levels [2]. Group 2: Company Overview and Market Performance - Soleno Therapeutics operates as a clinical-stage biopharmaceutical company focused on developing novel therapeutics for rare diseases, founded in 1999 and based in Redwood City, California [3]. - The company's fourth-quarter sales of Vykat XR exceeded consensus expectations, although there are concerns regarding weaker new patient starts impacting stock performance [2]. - Wolfe Research noted that the current market valuation reflects a bear-case scenario for product uptake, while its base-case outlook anticipates a more moderate decline in new patient starts than currently priced in by the market [2].

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is among the stocks under $50 to buy now. On January 20, TheFly reported that H.C. Wainwright lifted the price target on Soleno Therapeutics, Inc. (NASDAQ:SLNO) to $120 from $110 and maintained a Buy rating. The new target suggests an upside potential of 177%. This positive outlook comes right after Soleno Therapeutics, Inc. (NASDAQ:SLNO) announced its preliminary 4Q25 and full-year 2025 financial results for its VYKAT XR offering, in which the company’s preliminar ...

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! AI is eating the world—and the machines behind it are ravenous. Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink. Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and b ...

Core Viewpoint - The law firm Kirby McInerney LLP is investigating Soleno Therapeutics, Inc. for potential violations of federal securities laws or unlawful business practices related to its product Vykat XR [1]. Group 1: Company Performance and Events - On August 15, 2025, Scorpion Capital published a report labeling Soleno's Vykat XR as overpriced and potentially unsafe for children, leading to a share price decline of $5.73, or approximately 7.41%, from $77.36 to $71.64 [3]. - During a quarterly earnings call on November 4, 2025, Soleno disclosed that the discontinuation rate of Vykat XR due to adverse effects was around 8% at the end of Q3 2025. The CEO noted a disruption in the product's launch trajectory following the Scorpion Capital report, resulting in a further share price drop of $16.98, or approximately 26.59%, from $63.85 to $46.87 [4].

Core Viewpoint - The stock price of Soleno Therapeutics, Inc. (SLNO) has been on a bearish trend, losing 10% over the past week, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be emerging [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out, with selling pressure likely subsiding, which could lead to a bullish trend for SLNO [2][5]. - A hammer pattern forms when there is a small difference between opening and closing prices, with a long lower wick, suggesting that bears may be losing control [4][5]. - The occurrence of a hammer pattern at the bottom of a downtrend signals that bulls may have successfully halted further price declines, indicating a potential trend reversal [5]. Fundamental Analysis - There has been a recent upward trend in earnings estimate revisions for SLNO, which is a bullish indicator as it correlates strongly with near-term stock price movements [7]. - Over the last 30 days, the consensus EPS estimate for the current year has increased by 3%, indicating that analysts expect better earnings than previously predicted [8]. - SLNO holds a Zacks Rank of 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Core Viewpoint - Soleno Therapeutics, Inc. is under investigation for potential violations of federal securities laws following negative reports about its product Vykat XR, which has led to significant declines in its stock price [1][2]. Group 1: Company Performance - On August 15, 2025, a report by Scorpion Capital labeled Vykat XR as overpriced and potentially unsafe for children, resulting in a stock price drop of $5.73, or approximately 7.41%, from $77.36 to $71.64 [1]. - During the quarterly earnings call on November 4, 2025, Soleno disclosed a discontinuation rate of approximately 8% for Vykat XR due to adverse effects, which contributed to a further decline in stock price by $16.98, or approximately 26.59%, from $63.85 to $46.87 [2]. Group 2: Management Response - The CEO of Soleno acknowledged a disruption in the launch trajectory of Vykat XR following the negative report from Scorpion Capital, citing a decrease in start forms and an increase in discontinuations for non-serious adverse events [2].

Financial Results - Soleno Therapeutics, Inc. announced preliminary financial results for Q4 and the full year ended December 31, 2025[4] - The press release detailing these results was issued on January 12, 2026[4] Company Information - The company is listed on NASDAQ under the ticker symbol SLNO[2]

Core Insights - Soleno Therapeutics has reported strong preliminary financial results for Q4 and full-year 2025, driven by the successful launch of VYKAT XR for treating Prader-Willi syndrome (PWS) [1][5] - The company has achieved significant market penetration, with over 10% of the addressable U.S. PWS patient population having initiated treatment with VYKAT XR within nine months of its launch [1][5] - Soleno is well-funded with approximately $500 million in cash and equivalents at year-end 2025, and has achieved profitability and positive cash flow [5] Financial Performance - Preliminary unaudited net revenue for full-year 2025 from U.S. sales of VYKAT XR is expected to be between $189 million and $191 million [5] - Preliminary unaudited net revenue for Q4 2025 is anticipated to be between $90 million and $92 million [5] - The company reported a total of 1,250 new patient start forms since the launch, with 207 forms submitted in Q4 2025 [5] Market and Product Information - VYKAT XR was approved by the FDA on March 26, 2025, and is indicated for the treatment of hyperphagia in patients aged 4 years and older with PWS [4][6] - The discontinuation rate of VYKAT XR due to adverse events was approximately 12% by the end of Q4 2025 [5] - The product has been prescribed by 630 unique prescribers, including 136 new prescribers in Q4 2025 [5] Patient Demographics and Impact - The Prader-Willi Syndrome Association USA estimates that PWS occurs in one in every 15,000 live births, highlighting the significant unmet medical need for effective treatments [3] - Hyperphagia, the defining symptom of PWS, poses serious health risks, including mortality and long-term co-morbidities such as diabetes and obesity [3]

Core Viewpoint - Kirby McInerney LLP is investigating Soleno Therapeutics, Inc. for potential violations of federal securities laws or unlawful business practices related to its product Vykat XR [1] Group 1: Company Performance and Events - On August 15, 2025, Scorpion Capital published a report labeling Vykat XR as overpriced and potentially unsafe for children, leading to a decline in Soleno's share price by $5.73, or approximately 7.41%, from $77.36 to $71.64 [3] - During the quarterly earnings call on November 4, 2025, Soleno disclosed a discontinuation rate of approximately 8% for Vykat XR due to adverse effects, which contributed to a further decline in share price by $16.98, or approximately 26.59%, from $63.85 to $46.87 [4]